Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Typhoid Vi Polysaccharide Vaccine

Phase 1Vaccine

2

Indications

6

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

FearRecruiting

Japanese EncephalitisPreclinical

Active, not recruiting

FearPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2026

ApprovedActive, not recruiting

Monkeypox

NCT05745987

Q4 2028

Phase 1Recruiting

Fear

NCT06630884

Clinical

Trials by Indication[1]

Inflammation2 trials

Cognitive, Emotional, and Neural Responses to Acute Inflammation

Completed·UUniversity of California, San Francisco·Phase 1·NCT03294564·24 enrolled

Inflammation and Threat Sensitivity in PTSD

Completed·UUniversity of California, San Francisco·Phase 1·NCT03048929·30 enrolled

Fear1 trial

Inflammatory Challenge and Fear

Recruiting·UUniversity of California, San Francisco·Phase 1·NCT06630884·288 enrolled

Japanese encephalitis1 trial

Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity

Unknown status·UUniversity of Oxford·N/A·NCT06027801·150 enrolled

Immunogenicity1 trial

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Completed· Novartis logo

Novartis·Phase 3·NCT01466387·552 enrolled

Monkeypox1 trial

SMART (Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster Randomized Controlled Trial)

Active, not recruiting·MMcMaster University·Approved·NCT05745987·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Typhoid Vi Polysaccharide Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Typhoid Vi Polysaccharide Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Typhoid Vi Polysaccharide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: Novartis

Related News